Tamás Resál

Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study

B Farkas, Talat Bessissow, Jimmy K. Limdi et al. · Journal of Clinical Medicine · 2024 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study

Livia Lontai, Lóránt Gönczi, F Balogh et al. · Digestive and Liver Disease · 2022 · 17 citations · Full text

Medicine, Clinical Sciences, Immunology +15

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls

Péter Bacsúr, M Rutka, András Asbóth et al. · Therapeutic Advances in Gastroenterology · 2023 · 15 citations · Full text

Life Sciences, Immunology, Microbiology +17

Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study

Tamás Resál, Péter Bacsúr, Csilla Keresztes et al. · Inflammatory Bowel Diseases · 2023 · 15 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +14

Ustekinumab is associated with superior treatment persistence but not with higher remission rates <i>versus</i> vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study

Péter Bacsúr, Mária Matúz, Tamás Resál et al. · Therapeutic Advances in Gastroenterology · 2022 · 12 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17